FDA approves Zenbexus for multiple myeloma as NSAI looks to sell MDR notified body unit
The U.S. Food and Drug Administration has granted approval for Zenbexus to be used in the treatment of multiple myeloma, marking a new therapeutic option for patients with this blood cancer.
The approval signals regulatory confidence in Zenbexus' safety and efficacy profile, though detailed clinical data were not provided in the announcement.
Separately, NSAI announced it is seeking a buyer for its medical device regulation (MDR) notified body business, indicating a strategic move to divest that segment.
The potential sale could reshape the landscape of MDR services, offering opportunities for other firms to expand their capabilities in the European regulatory space.
This writeup was produced by pharmadog from original reporting by raps.
Original headline: “Recon: FDA approves Zenbexus for multiple myeloma; NSAI seeks buyer for its MDR notified body business”
read at raps ↗
comments(0)
5-min edit window · permanent after that